Form 4: TriSalus Life Sciences Executive Jodi Devlin Reports Acquisition and Disposal of Common Stock
SEC Form 4 Filing
Jodi Devlin, Chief of Clinical Operations at TriSalus Life Sciences, reports acquiring and disposing of common stock on February 18, 2025, according to a Form 4 filing.
Summary
- Jodi Devlin, the Chief of Clinical Operations at TriSalus Life Sciences, filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on February 18, 2025.
- Devlin acquired 5,272 shares of common stock through a restricted stock unit (RSU) award.
- The price of the acquired shares was $0.
- Devlin also disposed of an unspecified amount of common stock.
- Following the reported transactions, Devlin beneficially owns 33,397 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The RSU award suggests the company is incentivizing its Chief of Clinical Operations with equity.
Future Outlook
The vesting schedule of the RSU award extends into 2026, indicating a long-term incentive for the reporting person.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in the beneficial ownership of TriSalus Life Sciences' stock by one of its officers.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 02/18/2025 | Date of transaction: acquisition and disposal of common stock, grant date of restricted stock units |
| 02/19/2025 | Date of signature on the Form 4 filing |
| 05/15/2025 | First vesting date of 25% of the shares subject to the RSU Award |
| 08/15/2025 | Second vesting date of 25% of the shares subject to the RSU Award |
| 11/14/2025 | Third vesting date of 25% of the shares subject to the RSU Award |
| 02/13/2026 | Final vesting date of the remaining shares subject to the RSU Award |
Keywords
Form 4, TriSalus Life Sciences, Jodi Devlin, stock, RSU, beneficial ownership, TLSI
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.